| Literature DB >> 32425395 |
Sreejesh Sreedharanunni1, Man Updesh Singh Sachdeva1, Saniya Sharma1, Sonia Rana1, Rajeev Sandal2, Narender Kumar1, Prashant Sharma1, Shano Naseem1, Jasmina Ahluwalia1, Reena Das1, Pankaj Malhotra2, Neelam Varma1.
Abstract
To study the clinico-haematological and histopathological characteristics of FIP1L1-PDGFRA rearranged hypereosinophilia/hypereosinophilic syndrome (F/P+ve HE/HES), a retrospective analysis of patients with F/P+ve HE diagnosed over a period of 43 months was performed. Peripheral blood smears, bone marrow aspirate (BMA) and biopsies (BMB) were reviewed in each case and; reticulin stain and immunohistochemistry for mast cell tryptase (MCT) and CD117 was performed. F/P+ve HE was diagnosed in a total of ten patients during study period. All patients were males with a median age of 36 years (23-44 years). The median duration of presenting complaints was 7 months (2 months-3 years) which included specific symptoms related to various organs (80% of cases). Anaemia, thrombocytopenia and splenomegaly were seen in 60%, 50% and 90% of the cases respectively. Mastocytosis was not obvious in BMA but identified by MCT on BMB in all cases. Myelofibrosis (grade ≥ 1) was seen in 80% of the cases and includes multifocal paratrabecular fibrosis in 50% of the biopsies. Our study shows that bone marrow mastocytosis and myelofibrosis are very useful morphological indicators to suspect F/P+ve HE and suggests the routine use of reticulin staining and MCT immunohistochemistry in all BMBs performed for the evaluation of HE/HES. © Indian Society of Hematology and Blood Transfusion 2019.Entities:
Keywords: FIP1L1-PDGFRA rearrangement; Hypereosinophilia; Mast cell tryptase; Mastocytosis; Myelofibrosis
Year: 2019 PMID: 32425395 PMCID: PMC7229073 DOI: 10.1007/s12288-019-01236-0
Source DB: PubMed Journal: Indian J Hematol Blood Transfus ISSN: 0971-4502 Impact factor: 0.900